Cervical cancer is the second most common type of malignant tumor among women worldwide. When the disease is confined locally, it can be controlled with surgical resection and radiotherapy. However, patients with recurrent or metastatic disease often have a poor prognosis. Measurement of serum levels of squamous cell carcinoma (SCC) antigens has been widely used as serological markers for SCC of uterine cervix. Recently, it has been demonstrated that cervical cancer patients with elevated squamous cell carcinoma antigen-2 (SCCA2) expression in tumor cells carry a poor prognosis. Here, by using a luciferase reporter assay, we show that SCCA2 promoter was active in SCCA2-producing human cervical cancer cell lines, including Cx, Cxwj, SiHa and HeLa cells, but relatively quiescent in normal cervical epithelial cells. We then developed a conditionally replicating adenovirus, designated Ad-KFH, under the transcriptional control of the SCCA2 promoter. This E1B-55 kDa-deleted oncolytic adenovirus replicated specifically in and lysed SCCA2-producing cervical cancer cells. Furthermore, in a peritoneal metastatic tumor model, Ad-KFH retarded Cxwj tumor growth in NOD/severe combined immunodeficient mice and prolonged survival of tumor-bearing mice, especially when combined with cisplatin. These results suggest that Ad-KFH may provide a new strategy of gene therapy for advanced or recurrent uterine cervical cancer.
Introduction
Cervical cancer is the leading cause of gynecological cancer mortality. There are approximately 500 000 new cases of cervical cancer per year worldwide and approximately 200 000 deaths each year. 1 Up to 80% of the tumors have been classified as squamous cell carcinoma (SCC). 2 The squamous cell carcinoma antigen (SCCA) was first isolated from uterine cervical cancer by Kato et al. 3 in 1977 as a circulating tumor marker for SCC. Serum concentrations of this marker correlate well with clinical stages of the disease, the presence or absence of risk factors, the effect of treatment and the course of the disease. [4] [5] [6] Furthermore, in SCC of the lung, cervix, head and neck or esophagus, the SCCA values were related to tumor stage [7] [8] [9] [10] and were highest in patients with metastases. 11 Cloning of the SCCA cDNA demonstrated that it belongs to the family of serine protease inhibitors (serpins). 12 Further cloning of the genomic region of chromosome 18q21.3 revealed two tandemly arrayed SCCA genes, designated SCCA1 and SCCA2. 13 Although SCCA1 and SCCA2 are nearly identical, they differ in their reactive site loop and exhibit different functions. SCCA1 inhibits the papain-like cysteine proteinases cathepsin S, K, and L, whereas SCCA2 inhibits the chymotrypsin-like serine proteinases cathepsin G and mast cell chymase. SCCA2 were upregulated in cervical cancer tissues compared with those in normal cervical cells. 16 Using laser microdissection and quantitative real-time reversetranscriptase PCR (RT-PCR) techniques, we also found that the value of SCCA2/SCCA1 ratio increased as the stage of cervical carcinogenesis increased and that patients with high SCCA2/SCCA1 ratios carried a poor prognosis. 17 It appears that SCCA2 expression is more specific than SCCA1 expression in uterine cervical cancer.
Over the last century, radical surgery and radiotherapy have been used to improve survival rates in patients with primary cervical cancer. However, those with advanced, recurrent or metastatic disease often have a low survival rate. Thus, new strategies for treatment of advanced, recurrent or metastatic cervical cancer in addition to traditional therapeutic modalities are needed.
Conditionally replicating adenoviruses (CRAds) represent a promising alternative treatment in cancer therapy. 18 Two basic strategies have been used to generate CRAds. The first approach, for example, Ad-dl1520 (ONYX-015), is designed to achieve tumor-specific replication by introduction of viral genomic deletions that affect viral protein functions dispensable in cancer cells. 19 The other effective way of CRAds are designed to achieve replicative specificity based on heterologous tissue-specific promoters into the adenovirus genome to drive gene expressions required for the viral life cycle, including E1A and E1B. The second approach is expected to achieve more specific oncolytic effects.
In this study, oncolytic adenovirus was designed to make use of SCCA2 promoter to achieve tumor-specific viral replication. We constructed and characterized Ad-KFH, a novel E1B-55 kDa-deleted adenovirus, in which the viral E1A promoter was replaced with the human SCCA2 promoter. Our results show that Ad-KFH preferentially replicated in and lysed SCCA2-overexpressing cervical cancer cells in vitro. Furthermore, intraperitoneal administration of Ad-KFH, in particular when combined with cisplatin, retarded tumor growth and prolonged the survival of NOD/severe combined immunodeficiency (SCID) mice bearing cervical carcinoma implanted intraperitoneally (i.p.).
Materials and methods

Cells and cell culture
Four cervical cancer cell lines were used in this study. SiHa and HeLa cells derived from human cervical carcinoma of the uterus were purchased from ATCC (Rockville, MD, USA). Cx cells were established in this laboratory from a cervical cancer patient. 20 Cxwj cells were further developed by in vitro and in vivo selection from Cx cells. Human 293 embryonic kidney cell line was obtained from ATCC. All cell lines were maintained at 37 1C in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Sigma Chemical Co., St Louis, MO, USA). Normal cervical epithelial cells were derived from patients who underwent hysterectomy and cultured in serum-free keratinocyte medium (Keratinocyte-SFM; Invitrogen) as described previously. 21 
Generation of Cxwj cells
As Cx cells have no detectable human papillomavirus (HPV) DNA 20 and are nontumorigenic in NOD/SCID mice, we established a tumorigenic variant derived from CX cells through in vivo passages and introduction of HPV type 16 E6 and E7. Cx cells (5 Â 10 6 ) mixed with Metrigel in 0.1 ml were inoculated subcutaneously at the flank area of NOD/SCID mice. A small tumor mass that developed B60 days later was explanted, cultured and expanded in vitro. We selected the fastest growing clone of the tumor cells and reinjected the cells into mice. The tumors developed after 30 days. They were explanted, cultured and expanded again in vitro. After two series of in vitro and in vivo selections, the tumor cells were further transduced with an amphotropic LXSN retroviral vector expressing HPV type 16 E6 and E7. 22 The transduced tumor cells, designated Cxwj, were subsequently selected by G418 at 200 ng ml À1 for 2 days and 50 ng ml À1 for an additional 3 days before further serial passages. Cxwj cells had spindle-like shape morphologically and a short doubling time compared with parental Cx cells. When NOD/SCID mice were inoculated subcutaneously or i.p. with 10 6 of Cxwj cells, all the mice developed tumors within 7 days.
Detection of SCCA1 and SCCA2 mRNA expressions by RT-PCR Reverse-transcriptase PCR analysis was used to examine the levels of SCCA1 and SCCA2 mRNA expressions in cervical cancer and normal cervical cells. Total RNA was isolated with TRIZOL reagent (Invitrogen) from each cell line. Two oligonucleotide primer pairs specific to the human SCCA1 (forward, 5 0 -ACGAGGTACCTCACCA TGAATTCACTCAG-3 0 ; reverse, 5 0 -AGCACTCGATCT ACGGGGATGAGAATCT-3 0 ) and SCCA2 (forward, 5 0 -TTCATTCCACAGACACACACAG-3 0 ; reverse, 5 0 -CTT GTTTGGCCAAAATTTTTCC-3 0 ) were used, which produced a 576-bp PCR product as described previously. 23 PCR was performed with amplification conditions 94 1C for 30 s, 54 1C for 30 s and 72 1C for 1 min for 35 cycles. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control standard. The PCR products were electrophoresed in a 1% agarose gel and visualized by ethidium bromide staining.
Analysis of SCCA2 gene expression by real-time quantitative RT-PCR To accurately quantify SCCA2 gene expression, we generated standard curves by serially diluting a known amount of RNA from in vitro transcription and performing TaqMan PCR in parallel with tested samples using forward (5 0 -AGCCACGGTCTCTCAG-3 0 ) and reverse (5 0 -GCAGCTGCAGCTTCCA-3 0 ) primer pairs, as well as TaqMan probe for SCCA2 (5 0 -AAGGCCTTTGTG GAGGTCACTGAGGAGGGA-3 0 ), which produced an amplicon size of 81 bp. 17 The specific probe was labeled with 6-carboxy-fluorescein at the 5 0 terminus and SCCA2 for cervical cancer therapy K-F Hsu et al quenching dye 6-carboxytetramethylrhodamine at the 3 0 terminus. Reverse transcription was performed using reverse transcriptase and random hexamers. A total of 20 ng total RNA and serially diluted standard SCCA2 RNA were incubated with reverse transcriptase for 1 h at 37 1C in a total volume of 20 ml. The housekeeping gene 18S ribosomal RNA was assessed as an internal control for RNA quality. All of the quantitative analyses were carried out in duplicate to determine consistency of results.
Plasmid construction
The nucleotide sequence for the SCCA2 gene was reported in the GenBank nucleotide sequence with accession number AB035089. The core promoter region of the SCCA2 gene encompassing À446 to þ 72 bp was obtained by PCR using genomic DNA from Cx cells as the template with forward primer 5 0 -AGAACT-GAAAAACAGGAAATG-3 0 and reverse primer 5 0 -CTTGAAGCTCTTACCTGTGT-3 0 .
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The resulting 518-bp fragment was cloned into pSTBlue-1 cloning vector (Novagen, Madison, WI, USA), yielding pSTBlue-1-SCCA2. The SCCA2 promoter region was excised from pSTBlue-1-SCCA2, inserted upstream of the luciferase gene of pGL3-enhancer reporter vector (Promega, Madison, WI, USA) to generate pGL3-SCCA2, and subsequently sequenced to verify its correctness.
Analysis of SCCA2 promoter activity in various cell lines
The activities of the SCCA2 promoter in each cell line were evaluated by a luciferase reporter assay. Cells (10 5 cells per well) were cotransfected with 1.3 mg of pGL3-SCCA2 and 0.3 mg of Renilla luciferase reporter vector pRL-TK (Promega) serving as an internal standard for transfection efficiency as described previously. 25 The luciferase activity from the firefly luciferase reporter gene was determined and normalized with Renilla luciferase activity using the dual luciferase reporter assay system (Promega). The relative luciferase activity is expressed as a ratio of luciferase activity of each cell line divided by that of normal cervical cells.
Recombinant adenoviral vectors
Ad-KFH, an E1B 55-kDa-deleted adenovirus driven by the SCCA2 promoter, was generated using the AdEasy system. 26, 27 The fragment encompassing the SCCA2 promoter was excised from pSTBlue-1-SCCA2 and subcloned into pAd5YS. 28 The fragment encompassing sequences of SCCA2 promoter, E1A, E1B 19 kDa and E1B 55 kDa that carried two point mutations at bases 2253 (C-T) and 2262 (G-T) of the nucleotide sequence of human adenovirus type 5 (GenBank accession no. AC 000008) to generate premature translation stop codons 25, 29 was excised from pAd5YS by BsrGI and MunI digestions and cloned into pShuttle to generate pShuttle-YS/SCCA2. The shuttle vector pShuttle-YS/SCCA2 was linearized with PmeI and subsequently cotransformed into E.coli strain BJ5183 with an adenoviral backbone plasmid pAdEasy-1. 26 Ad-LacZ, an E1-deleted, replication-defective adenovirus encoding b-galactosidase (b-gal), has been described previously. 25 The recombinant adenoviruses were propagated in 293 cells and purified by CsCl density gradient centrifugation. The purified virus stock was dialyzed, titrated by plaque assay and stored at À80 1C until use. 
Immunoblot analysis
To assess viral replication in cervical cancer cells, adenoviral late proteins were detected by immunoblot analysis. Cervical cancer cells (Cx, Cxwj, SiHa and HeLa), normal cervical cells and 293 cells were infected with Ad-KFH at an MOI of 100 and incubated for 5 days. Proteins (50 mg) from the cell lysates were fractionated on SDS-polyacrylamide gel electrophoresis, transferred onto Hybond enhanced chemiluminescence nitrocellulose membranes (Amersham, Little Chalfont, UK) and probed with rabbit polyclonal antibody ab6982 to adenovirus type 5 (Abcam, Cambridge, MA, USA), which reacts with all capsid proteins of adenovirus type 5, including hexon, fiber and penton. Mouse anti-human b-actin monoclonal antibody N350 (Amersham) was used to detect b-actin expression, which served as the loading control. The protein bands were visualized by the enhanced chemiluminescence system (Amersham).
Animal studies Female, 6-to 8-week-old NOD/SCID mice were obtained from the Laboratory Animal Center of the National Cheng Kung University. The animals were maintained in specific pathogen-free animal care facility under isothermal conditions with regular photoperiods. The experimental protocol adhered to the rules of the Animal Protection Act of Taiwan and was approved by the Laboratory Animal Care and Use Committee of the National Cheng Kung University. Mice were inoculated i.p. with Cxwj cells (10 6 ) at day 0. For tumor growth assessment, three groups of five mice were treated i.p. with 2 Â 10 9 plaque-forming units of Ad-KFH or Ad-LacZ alone at days 8, 10 and 12 or with cisplatin (4 mg kg À1 ) alone at days 9, 11 and 13. Another group of five mice received combined treatment of Ad-KFH and cisplatin. All of the mice were monitored by palpation twice a week for tumor growth. Mice were killed at day 24 and all the intraperitoneal tumors were obtained and their weight measured. For survival analysis, the treatment protocol was the same as that for tumor growth assessment. Mice were monitored, and the time of animal death was recorded.
Statistical analysis
The survival analysis was done using the Kaplan-Meier survival curve and the log-rank test. Other statistical differences were assessed with Student's t-test. Any P-value of o0.05 is regarded statistically significant.
Results
Different levels of endogenous SCCA2 gene expression in normal and cervical cancer cells Human Cx, Cxwj, SiHa and HeLa cervical cell lines, as well as normal cervical cells were examined for mRNA expressions of SCCA1 and SCCA2 by RT-PCR (Figure 1a ). Higher levels of 576-bp SCCA1 and SCCA2 amplicons were detected in Cx and Cxwj cells, whereas lower amounts of these amplicons were found in SiHa and HeLa cells as well as in normal cervical cells. To further analyze SCCA2 mRNA expression in cervical cells, we performed quantitative real-time RT-PCR as described previously. 17 In normal cervical cells, the mean value of SCCA2 mRNA per 20 ng of total RNA was 9.46 Â 10 À8 ng. In Cx and Cxwj cells, the expression of SCCA2 mRNA was greater than 800-and 500-fold higher than that in normal cervical cells, respectively (Figure 1b) . HeLa and SiHa cells also expressed SCCA2 mRNA, although at a much lower level compared with Cx and Cxwj cells.
Cervical cancer cell specificity of SCCA2 promoter activity The luciferase reporter assay was used to determine the activity of the SCCA2 promoter in various cells (Figure 1c) . In Cx and Cxwj cells, which expressed higher levels of endogenous SCCA2 mRNA, higher levels of SCCA2 promoter activity were observed, with B11-and B7-fold higher activity, respectively, compared with that of normal cervical cells. The SCCA2 promoter activity was weaker in HeLa and SiHa cells than in Cx and Cxwj cells, whereas normal cervical cells exhibited only negligible activity. Taken together, our results show that the expression levels of SCCA2 mRNA (Figures 1a and b) were well correlated with their promoter activities (Figure 1c ) in these cells.
Higher efficiency of adenovirus infection in cervical cancer cell lines than in normal cells
To exploit CRAds for treating cervical cancer, we first examined the efficiency of adenovirus infection in cervical Renilla luciferase reporter vector pRL-TK. Firefly luciferase activity was determined and normalized with Renilla luciferase activity. The relative luciferase activity is expressed as a ratio of luciferase activity of each cell line divided by that of normal cervical cells. Each value represents the mean±s.e. of three separate experiments. Note that the SCCA2 promoter activity was significantly higher in cervical cancer cells than in normal cervical cells.
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cancer cells by Ad-LacZ. As shown in Figure 2 , b-gal expression was detectable at similar levels in four cervical cancer cells examined after exposure to Ad-LacZ. Furthermore, the infection efficiency of the cells increased when higher doses of Ad-LacZ were applied. In contrast, when cells were infected with Ad-LacZ at an MOI of 10, the infection efficiency was B10-fold lower in normal cervical cells (N1 and N2) than in cervical cancer cells. Even at an MOI of 100, the infection efficiency in normal cervical cells only achieved B20%.
Cytolytic effect of Ad-KFH on cervical cancer cells in vitro
We next constructed and produced an E1B 55 kDadeleted adenovirus Ad-KFH under the transcriptional control of the SCCA2 promoter. Figure 3a shows the structure of Ad-KFH, in which the endogenous E1A promoter was replaced by the SCCA2 promoter to control the expression of E1A. We examined the viral replication and cytolytic effects of Ad-KFH on cervical cancer and normal cervical cells in vitro. In the positive control 293 cells containing the E1 region of adenovirus type 5, two adenoviral late proteins hexon (107 kDa) and penton (63 kDa) were readily detectable, as revealed by immunoblot analysis (Figure 3b ). Furthermore, these two proteins were also identified in all cervical cancer cell lines examined, but hardly detectable in normal cervical cells 5 days after infection with 100 MOI of Ad-KFH. These results indicate that productive replication of Ad-KFH took place in cervical cancer cells that expressed SCCA2, but not in normal cervical cells. Furthermore, significant cytolytic effects were observed in cervical cancer cell lines 5 days after infection with Ad-KFH, especially in Cxwj and Cx cells (Figure 3c ), both of which expressed higher levels of SCCA2 (Figure 1a ). Of note, the degree of cytotoxicity in these cancer cell lines was positively proportional to the viral dose. The cytolytic effect of Ad-KFH at higher doses appeared to be greater in Cxwj and Cx cells than in HeLa and SiHa cells. In contrast, cell viability remained unaffected in normal cervical cells (N1 and N2) after infection with various doses of Ad-KFH (Figure 3c ). Taken together, these results suggest that replication of Ad-KFH was restricted to cervical cancer cells.
Antitumor efficacy of Ad-KFH in mice bearing peritoneal Cxwj tumors We next used Cxwj tumors grown in peritoneal cavity to investigate the antitumor efficacy of Ad-KFH. CRAds in conjunction with standard chemotherapeutic agents have been demonstrated to enhance antitumor effects. To this end, we used cisplatin because it is frequently used in the clinical treatment of cervical cancer. Administration of Ad-KFH or cisplatin alone significantly retarded Cxwj tumor growth compared with Ad-LacZ treatment (Figures 4a and b) . Furthermore, when mice were treated with Ad-KFH in combination with cisplatin (4 mg kg
À1
), no tumors were grossly found at day 24 after tumor cell implantation. Mice receiving Ad-KFH or cisplatin alone had longer survival time compared with those receiving Ad-LacZ (Figure 4c) . Notably, Ad-KFH in combination with cisplatin dramatically prolonged the survival of tumor-bearing mice. Collectively, these results show that Ad-KFH treatment resulted in tumor growth retardation and prolongation of the survival in mice bearing peritoneal Cxwj tumors.
Discussion
In this study, we show that SCCA2 is active in cervical cancer cell lines and cells derived from primary cervical cancer. To utilize SCCA2 overexpression in cervical cancer as a basis for therapeutic interventions, we generated an E1B 55 kDa-deleted adenovirus by replacing its internal E1A promoter with SCCA2 promoter. This conditionally replicating adenovirus, Ad-KFH, only replicates and kills cervical cancer cells overexpressing SCCA2, whereas no or little cytolytic effect is detected in normal cervical cells expressing low levels of SCCA2. Furthermore, in intraperitoneal metastatic tumor model, treatment with Ad-KFH resulted in significant inhibition of tumor growth and enhancement of mouse survival. SCCA2 promoter has been used to control proapoptotic gene expression by adenoviral vectors for selective induction of apoptosis in SCCA2-expressing lung cancer cells. 30 As the majority (up to 80%) of cervical cancers overexpress SCC, it is reasonable to use this modality for treating cervical cancer clinically. To our knowledge, this is the first report to use the SCCA2 promoter to transcriptionally drive the replication of an oncolytic adenovirus specifically in metastatic cervical tumors.
It is notable that the promoter sequences of SCCA1 and SCCA2 are similar. At nucleotide position À50, the A residue in SCCA2 is replaced by a G residue in SCCA1, and this appears to be responsible for the difference in transcriptional activities of the two promoters. 30 The complete SCCA2 gene locus has been cloned and its putative promoter region has been analyzed. The SCCA2 core promoter region exhibited a higher promoter activity in SCCA2-producing SKGIIIa than in nonproducing SK-OV-3 or K42 cells. 31 Our quantitative RT-PCR data also demonstrate higher SCCA2 mRNA expression in cervical cancer cells compared with normal cells. Furthermore, the transcriptional activity of the SCCA2 promoter in cervical cancer cells was B3.5 to B11 times higher than that in normal cells. All these results support the use of the SCCA2 promoter to control transgene expression specific to cervical cancer cells that overexpress SCCA2.
Oncolytic adenovirus as an anticancer agent is a potential treatment modality for a number of human malignancies. 32 The most studied oncolytic adenovirus so far named ONYX-015 (also known as Ad-dl1520) 19 is an adenovirus with deleted E1B 55 kDa gene, which has shown promising results in the treatment of patients with recurrent head-and-neck cancer when combined with chemotherapy. 18 Virtually, all cases of cervical cancer are attributable to infection by a subset of HPV. 33 HPV E6 and E7 proteins can support the replication of E1-deleted adenovirus in tumor cells. 34 Therefore, uterine cervical cancer is a suitable target for therapy with CRAds.
Cervical cancer is the leading cause of cancer death in the female genital system. This disease is controlled by surgery or radiation therapy when confined locally. However, when tumor is beyond curative treatment with conventional therapy, that is, intraperitoneal recurrence, the prognosis is poor. Although chemotherapeutic agents, such as cisplatin, paclitaxel or topotecan, yield response rates and progression-free survival, the median survival is still less than 1 year in this group of patients. Most patients do not respond to treatment and thus are subjected to treatment-related toxicity without a meaningful benefit.
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E1B-deleted adenovirus in combination with cisplatin has been reported to enhance antitumor effects compared with either modality alone. 25, 36, 37 Moreover, several lines of evidence for a potentially synergistic effect of oncolytic adenovirus and cisplatin were demonstrated from clinical trials. 38 In addition, E1A gene may sensitize tumor cells to DNA-damaging agents through a p53-independent pathway. 39 Our in vivo combination therapy of Ad-KFH and cisplatin is in accordance with these findings.
In conclusion, our results indicate that SCCA2 promoter-driven Ad-KFH virus selectively replicated in and killed SCCA2-overexpressing human cervical cancer cells in vitro. More importantly, Ad-KFH retarded tumor growth and prolonged the survival in mice bearing peritoneal cervical tumors overexpressing SCCA2. Therefore, this study may have clinical implications in exploring SCCA2 promoter-driven oncolytic adenovirus for the treatment of recurrent or metastatic tumors, such as intraperitoneal cervical cancers due to overexpression of SCCA2 in uterine cervical cancers. 
